$1.70
-0.28-14.14%
Last update: Nov 9, 4:22 PM
Seres Therapeutics Inc
MCRBNASDAQ
Seres Therapeutics fell 87.9% from $14.05 to $1.70, behind the S&P 500's +10.5%. Its worst day was Feb 12 (−41.7%), and its low came Nov 9 at $1.70.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Seres Therapeutics closed at its highest level of the year, 103.8% above where the year started.
+15.9% · S&P 500 +0.4%
Seres Therapeutics shares fell 41.7%, while the S&P 500 fell 1.5%.
Story events cover the past 12 months · Times ET
−41.7%, the year's worst day · S&P 500 −1.5%
EPS of $-1.76 beat the $-1.92 estimate on $438,000.00 revenue (est. $5.9M).
+1.3% · S&P 500 −1.5%
EPS of $-2.08 missed the $-1.85 estimate on $358,000.00 revenue.
−2.5% · S&P 500 +0.8%
EPS of $0.47 beat the $-2.16 estimate on $736,000.00 revenue (est. $179,000.00).
−4.7% · S&P 500 −0.2%
EPS of $-1.63 missed the $-1.07 estimate on $593,000.00 revenue (est. $5.1M).
+6.6% · S&P 500 +1.7%
Where it ended: a close of $1.70 on Nov 9, 2026.
Nothing in the past 12 months.
All MCRB dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MCRB and SPY from Benzinga historical bars. Not investment advice.
